Rakesh Popat graduated from Guy’s and St. Thomas’ Medical School in London and trained in haematology at St. Bartholomew’s and the Royal London Hospitals. During this time he completed a PhD thesis focusing on designing scientifically based treatment combinations for multiple myeloma. This included pre-clinical work investigating bortezomib and chemotherapy combination treatments, and developing them into early phase clinical trials. He also worked on the pre-clinical development of a novel histone deacetylase inhibitor which has activity in multiple myeloma and lymphoma. He was awarded a fellowship to visit the Dana Farber Cancer Institute in Boston, USA where he gained experience both in their drug discovery laboratory and their clinical program. He is currently a Consultant Haematologist and Clinical Senior Lecturer at University College London Hospitals NHS Foundation Trust where he leads the early phase clinical trial program for haematological malignancies. He is the UK Chief investigator and local Principal Investigator of a number of Phase I and II clinical trials, the North Thames Clinical Research Network speciality lead for Haematology, research lead for London Cancer, member of the NCRI Myeloma sub-group and the Myeloma UK Clinical trials steering committee.